<DOC>
	<DOCNO>NCT00929240</DOCNO>
	<brief_summary>This randomize study compare maintenance therapy Avastin ( bevacizumab ) + Xeloda ( capecitabine ) versus Avastin alone , patient HER2-negative metastatic breast cancer progress first-line therapy docetaxel + Avastin . Eligible patient receive 6 x 3 week cycle treatment Avastin ( 15 mg/mg IV Day 1 cycle ) + docetaxel ( 75-100 mg/m2 IV Day 1 cycle ) . Those patient progress randomize 3 week cycle either ) Avastin ( 15 mg/kg IV Day 1 cycle ) + Xeloda ( 1000 mg/m2 po bid Days 1-14 cycle ) b ) Avastin alone . Study treatment continue disease progression , unacceptable toxicity , patient request withdrawal end study , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) + Xeloda ( Capecitabine ) Maintenance Therapy Patients With HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; HER2negative metastatic breast cancer candidate taxanebased chemotherapy ; ECOG performance status 0 1. previous chemotherapy metastatic breast cancer ; prior adjuvant/neoadjuvant chemotherapy within 6 month prior study ; prior radiotherapy treatment metastatic disease ; chronic daily treatment aspirin ( 325 mg/day ) clopidogrel ( &gt; 75mg/day ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>